Global News
-
23-07-2010Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox®[1]
Holzkirchen, July 23, 2010 – Sandoz today announced the introduction of enoxaparin sodium injection, the first generic version of Lovenox®[1], in the US. Product shipment began immediately following approval by the US Food and Drug Administration (FDA).
-
15-07-2010Novartis quarterly results Q2 2010
Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation.
-
28-06-2010Sandoz opens new state-of-the-art development center in East Hanover, NJ
Princeton, NJ, June 11, 2010 - Sandoz celebrated this week the formal launch of its new product development center located in East Hanover, New Jersey. The new development center will be a key site for Sandoz US development of generic medicines, with an emphasis on "first-to-file" applications with the FDA.
-
03-06-2010Sandoz completes acquisition of Oriel Therapeutics, strengthening potential for global leadership in respiratory
Princeton, New Jersey; June 3, 2010– Sandoz announced today that it has completed its acquisition of Oriel Therapeutics, a privately held US pharmaceuticals company, for an undisclosed sum.
-
26-05-2010NICE issues first biosimilar recommendation, saying Omnitrope® offers same efficacy and safety as other somatropins
Holzkirchen, May 26, 2010 – The UK’s National Institute for Health and Clinical Excellence (NICE) today published final guidance on the relative cost and effectiveness of somatropin products to treat child growth deficiencies1.
-
20-04-2010Novartis quarterly results Q1 2010
Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity
-
19-04-2010Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products targeting asthma and COPD
Holzkirchen, Germany, April 19, 2010 - Sandoz has signed a definitive agreement to acquire Oriel Therapeutics, a privately held US pharmaceuticals company, gaining exclusive rights to a portfolio of generic drug candidates and related technologies targeting medicines in the inhalable respiratory drug market. Terms of the deal were not disclosed.
-
08-04-2010Sandoz launches authorized versions of Cozaar® and Hyzaar® tablets
Princeton, NJ, April 7, 2010 —Sandoz Inc. announced today the introduction in the US of losartan potassium and losartan potassium-hydrochlorothiazide (HCTZ) tablets, authorized generic equivalents of Merck's Cozaar® and Hyzaar®.
-
01-04-2010Generic Medicines: Essential contributors to the long-term health of society
IMS's Alan Sheppard looks at the sustainability of the generics sector and assesses its benefits to the provision of healthcare across Europe.
-
26-03-2010Sandoz statement on passage of US biosimilars pathway legislation
We welcome the passage of a US biosimilars pathway, which means that patients and payors in the US are now set to gain access to safe and effective biosimilars, such as those pioneered by Sandoz in Europe and elsewhere.
